| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15842 R65219 |
Bromley (Levetiracetam) (Controls exposed to LTG), 2023 | Neonatal special care admission | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.55 [0.23;1.34] C excluded (control group) |
8/70 20/106 | 28 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15843 R65232 |
Bromley (Levetiracetam) (Controls unexposed, sick), 2023 | Neonatal special care admission | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.59 [0.52;4.83] C | 8/70 6/80 | 14 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12619 R47577 |
Van Marter (Levetiracetam) (Controls unexposed, disease free), 2021 | Need for special care nursery or neonatal intensive care unit (NICU) admission | at least 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
0.87 [0.36;2.09] C excluded (control group) |
10/87 13/100 | 23 | 87 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12616 R47559 |
Van Marter (Levetiracetam) (Controls unexposed, sick), 2021 | Need for special care nursery or neonatal intensive care unit (NICU) admission | at least 1st trimester excluded | prospective cohort | unexposed, sick | Adjustment: No |
0.78 [0.15;4.00] C excluded (exposition period) |
10/87 2/14 | 12 | 87 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8083 R24692 |
Aydin (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.09 [0.00;2.41] C excluded (control group) |
0/10 2/7 | 2 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8081 R24672 |
Aydin (Levetiracetam) (Controls unexposed, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 0.41 [0.02;9.43] C | 0/10 2/22 | 2 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5932 R15137 |
Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.08 [0.22;5.26] C excluded (control group) |
2/12 24/154 | 26 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5913 R14928 |
Artama (Levetiracetam) (Controls unexposed, disease free), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
2.37 [0.52;10.92] excluded (control group) |
2/12 49,612/689,482 | 49,614 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5921 R15024 |
Artama (Levetiracetam) (Controls unexposed, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.86 [0.39;8.92] | 2/12 152/1,708 | 154 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.50 [0.63;3.59] | 170 | 92 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Levetiracetam) (Controls unexposed, sick; 2: Levetiracetam) (Controls unexposed, sick; 3: Levetiracetam) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 5932, 5913, 8083, 12619, 15842